Sterling Biotech

What Sterling Biotech does

Sterling Biotech Limited is an India-based diversified biotechnology company operating three distinct businesses out of Gujarat and Mumbai. The Sterling Gelatin division, founded in 1995 in Vadodara, produces pharmaceutical-grade, food-grade, cosmetics-grade, and photography-grade gelatin from a state-of-the-art manufacturing facility at Padra (Karakhadi); it supplies global food, pharmaceutical capsule, cosmetics, and photographic materials customers. The Pharmaceutical division operates a WHO GMP-certified facility at Jambusar State Highway (Vadodara) producing fermentation-derived statins (Simvastatin Ammonium Salt, Lovastatin) and a portfolio of oncology APIs (Daunorubicin HCl, Doxorubicin HCl, Epirubicin HCl, Idarubicin HCl, Zoledronic Acid) with CEP and RO-CEP certifications; this division is managed by Zydus Lifesciences. The ORCA division, headquartered at Bharuch (Dahej), runs a precision fermentation platform originally developed with Perfect Day Inc that produces animal-free beta-lactoglobulin whey protein molecularly identical to conventional dairy, with third-party LCA-verified sustainability claims (97% fewer GHG emissions, 99% less water usage, 60% less energy). ORCA holds GRAS status in the United States and regulatory clearances in Singapore and the UAE, with active commercial partnerships across North America, Europe, and Asia.

Sterling Biotech makes money via B2B one-time sales contracts across all three divisions. Gelatin and pharmaceutical APIs are sold directly to manufacturers and distributors via dedicated sales contacts, with CEP, WHO GMP, and RO-CEP certifications supporting premium pricing and export access. ORCA animal-free dairy proteins are sold direct to food and beverage manufacturers (ice cream, yogurt, cream cheese, protein bars, RTD beverages, confectionery, sour cream, and egg replacer applications) on negotiated contract terms. Following Zydus Lifesciences' August 2024 acquisition of a 50% stake from Perfect Day Inc for INR 550 crore (USD ~66M), the company is structured as a 50-50 joint venture with equal board representation, where Zydus manages pharmaceutical operations, Perfect Day supplies precision fermentation technology, and Temasek-aligned leadership provides institutional governance. Sterling Biotech reported revenue of approximately INR 450 crore (USD ~54M) in 2023, employs 2,350+ people across its Indian locations, and is in active build-out of a new precision fermentation facility to serve global alternative-protein demand.

The go-to-market strategy is enterprise-direct sales: each API molecule and the ORCA brand have named sales contacts; pricing is contractually negotiated (not publicly disclosed); distribution leverages Zydus's global pharma network and Perfect Day's alternative-protein commercial relationships. Customer segments are horizontal across pharma manufacturers, food and beverage manufacturers, cosmetics/photography buyers, and a node in alternative-protein's emerging supply chain.

Name

Sterling Biotech

Legal name

Sterling Biotech Limited

Website

https://sterlingbiotech.in

Company type

Private

Founded year

1995

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Sterling Biotech is an India-based, three-division biotechnology company producing pharmaceutical-grade gelatin (Vadodara), precision-fermented animal-free dairy proteins via its ORCA joint venture (Bharuch), and fermentation-based APIs including statins and oncology drugs managed by Zydus Lifesciences (Vadodara), serving global food, pharmaceutical, cosmetics, and alternative-protein manufacturers.

Ownership category

akta.pro rank

Product category

Biopharmaceutical and Specialty Ingredients Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Plant-Based Dairy-Alternative Ingredients & Bases Manufacturing (Emulsions, Fat Systems, Protein/Starch Bases for B2B) (AFAHAJAI)

akta.pro secondary industries

Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK), Gelatin & Collagen Hydrolysates (Animal-Based Gelling Agents) (AFAJABAD)

Keywords

• Precision fermentation proteins
• Animal-free dairy proteins
• Pharmaceutical API manufacturing
• Gelatin manufacturing
• Fermentation-based oncology drugs

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Gelatin Products: Manufacturing and sale of high-quality gelatin products for food, pharmaceuticals, cosmetics, and photography industries. Sterling Gelatin, a division of Sterling Biotech Ltd, has built a global reputation as a leading gelatin manufacturer. Revenue recorded at approximately ₹450 crore in 2023.
2. Precision Fermented Animal-Free Dairy Proteins (ORCA): Sale of precision-fermented whey protein (beta-lactoglobulin) to global food and beverage manufacturers for use in ice cream, yogurt, cream cheese, protein bars, RTD beverages, confectionery, sour cream, and egg replacer applications. Commercial partnerships active in North America, Europe, and Asia.
3. Active Pharmaceutical Ingredients (APIs): Manufacturing and sale of fermentation-based APIs including statins (Simvastatin Ammonium Salt, Lovastatin) and oncology drugs (Daunorubicin HCl, Doxorubicin HCl, Epirubicin HCl, Idarubicin HCl, Zoledronic Acid) to pharmaceutical companies. WHO GMP certified facility. Products sold to global pharma manufacturers with CEP and RO-CEP certifications.
4. Zydus JV Revenue Share: Following Zydus Lifesciences' 50% stake acquisition in August 2024 for ₹550 crore ($66M), the joint venture creates shared revenue streams from the ORCA precision fermentation business and potential pharma business managed by Zydus. Equal board representation between Perfect Day and Zydus.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Sterling Biotech Limited operates three distinct divisions: (1) ORCA — precision-fermented animal-free dairy proteins (beta-lactoglobulin whey) via microbial fermentation for global food and beverage manufacturers; (2) Sterling Gelatin — high-quality gelatin for food, pharmaceutical, cosmetics, and photography industries; and (3) Pharmaceutical APIs — WHO GMP certified fermentation-based active pharmaceutical ingredients including statins (Simvastatin, Lovastatin) and oncology drugs (Doxorubicin, Epirubicin, Idarubicin, Daunorubicin, Zoledronic Acid), managed by Zydus Lifesciences.

Product overview

Sterling Biotech operates a diversified portfolio organized into three main divisions: (1) ORCA, a precision fermentation platform producing animal-free dairy proteins including whey protein (beta-lactoglobulin) through microbial fermentation; (2) Sterling Gelatin, manufacturing high-quality gelatin for food, pharmaceuticals, cosmetics, and photography industries; and (3) Pharmaceutical Business (managed by Zydus Lifesciences), producing fermentation-based APIs (statins) and oncology products including Daunorubicin HCL, Doxorubicin HCL, Epirubicin HCL, Idarubicin HCL, and Zoledronic Acid. The company also operates under a joint venture with Perfect Day and Zydus Lifesciences, focusing on animal-free protein production.

Differentiator

Problem solved

Functional benefit

Brands

• ORCA: Animal Free Dairy brand producing precision-fermented whey protein (beta-lactoglobulin) that is molecularly identical to traditional dairy protein but free from lactose, cholesterol, hormones, and antibiotics
• Sterling Gelatin
• Sterling Biotech Pharmaceutical

Products and services

• ORCA Animal-Free Dairy Protein (Beta-Lactoglobulin Whey)

Quantifiable outcome

• 97% fewer greenhouse gas emissions, 99% less water usage, and 60% less energy compared to conventional dairy production (third-party LCA verified)
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• Perfect Day InccoreTechnology or Integration · 1 August 2024Perfect Day Inc (California-based precision fermentation startup) co-created the ORCA division with Sterling Biotech. In August 2024, Perfect Day sold its 50% stake to Zydus Lifesciences for ₹550 crore ($66M), retaining technology licensing arrangements. Perfect Day developed the precision fermentation technology for producing animal-free milk proteins via microflora programming. The ORCA brand continues to use Perfect Day's technology for beta-lactoglobulin whey protein production.
• Zydus Lifesciences LimitedcoreStrategic or Co-development Partner · 1 August 2024Zydus Lifesciences acquired a 50% stake in Sterling Biotech from Perfect Day for ₹550 crore ($66M) in August 2024, creating an equal joint venture with Perfect Day. Zydus manages the pharmaceutical division of Sterling Biotech (pharma.sterlingbiotech.in). Joint venture has equal board representation. The deal represents a 70% premium over Perfect Day's 2022 purchase price of $78M. Zydus share price fell 5.9% on the news. Zydus's entry brings fermentation-based protein manufacturing and alternative protein portfolio expansion to Sterling Biotech, aligning with India's BioE3 policy.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Perfect Day: California-based pioneer of precision-fermented animal-free dairy proteins (beta-lactoglobulin whey). Direct competitor in the same product category as Sterling's ORCA division, and also Sterling's prior JV partner and current technology licensor.
• Gelita: Germany-headquartered global leader in gelatin manufacturing for food, pharma, cosmetics and technical applications. Directly comparable to Sterling Gelatin across the same product category and customer set.
• Remilk: Israel-based precision-fermentation company producing animal-identical milk proteins (including whey/casein). Directly competes with Sterling's ORCA in the B2B ingredient category for dairy-alternative and traditional dairy manufacturers globally.
• Rousselot (Darling Ingredients): World's largest gelatin producer, part of Darling Ingredients. Directly competes with Sterling Gelatin in food-grade and pharma-grade gelatin and has expanded into collagen peptides—a natural adjacency to Sterling's positioning.

Emerging players

• Helaina: US-based precision-fermentation company producing human milk protein (lactoferrin) and other functional proteins. Shares technology-platform DNA with ORCA's precision-fermentation stack and targets adjacent B2B applications in infant nutrition and functional foods.
• Geltor (Onekind): US-based startup producing animal-free proteins (collagen, elastin, whey) via precision fermentation. Comparable technology platform to ORCA and competes for the same B2B food, nutrition, and personal-care customers.

Broad incumbents

• Divi's Laboratories: India-based fermentation-led API and intermediate manufacturer with WHO-GMP/CEP-certified facilities comparable to Sterling's pharma division. Same end markets in regulated generic APIs and similar export-heavy B2B commercial motion.
• Aurobindo Pharma Limited: India-based large-scale API and finished dosage manufacturer with fermentation expertise; Sterling's SVP-Operations (Ravikumar Rao) is a former Aurobindo leader. Comparable fermentation-API manufacturing footprint and customer set in regulated generic markets.
• Zydus Lifesciences Limited: India's 5th-largest pharma company and Sterling Biotech's 50% JV partner since August 2024. Comparable API manufacturing and fermentation capabilities, and explicitly manages Sterling's pharmaceutical division under the JV structure.
• Tessenderlo Group / PB Leiner: Belgian specialty group whose PB Leiner division is a major gelatin and collagen peptide producer. Comparable to Sterling Gelatin across food/pharma-grade gelatin, with broader portfolio across crop solutions and other specialty chemicals.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/sterling-biotech-ltd---india

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sterling Biotech